Concord Biotech Ltd will host a virtual meeting for analysts and institutional investors on June 17, 2026, at 10:30 AM IST. The company stated that the interactions will be based on publicly available information and no unpublished price sensitive information (UPSI) is intended to be discussed.

The meeting is scheduled under the provisions of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The intimation was submitted to the stock exchanges pursuant to Regulation 30(6) of these regulations.

Meeting Details

The following table outlines the schedule for the interaction:

Paritosh Trivedi, Company Secretary & Compliance Officer, signed the intimation on June 13, 2026. The company noted that changes to the schedule may occur due to exigencies on the part of the participants or the company.

Concord Biotech has successfully completed an inspection by Brazil's National Health Surveillance Agency (ANVISA) at its Limbasi Active Pharmaceutical Ingredient (API) manufacturing facility. The inspection, which took place from June 8 to June 12, 2026, marks a significant milestone in the company's global growth journey by opening access to one of the world's largest pharmaceutical markets.

Regulatory Milestone at Limbasi Facility

The ANVISA inspection at the Limbasi API manufacturing site is a critical requirement for companies seeking to supply pharmaceutical ingredients to the Brazilian market. Successful completion of this inspection demonstrates that the facility meets Brazil's stringent regulatory and quality standards for pharmaceutical manufacturing. The inspection was concluded successfully on June 12, 2026.

Significance for Global Expansion

The successful ANVISA inspection is expected to bolster Concord Biotech's global regulatory standing and expand its footprint in international pharmaceutical markets. Brazil represents a strategically important market given its scale and demand for high-quality API products. Clearing this inspection positions the company to potentially supply its API portfolio to Brazilian pharmaceutical manufacturers and further diversify its international revenue base.

This development aligns with Concord Biotech's broader objective of strengthening its global manufacturing credentials by adhering to multiple international regulatory frameworks. The Limbasi facility's compliance with ANVISA standards adds to the site's regulatory approvals, reinforcing its status as a globally recognized manufacturing hub.